Lucas Eduardo Botelho de Souza
Overview
Explore the profile of Lucas Eduardo Botelho de Souza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Teibo J, Picanco-Castro V, de Souza L, Faca V
J Proteome Res
. 2025 Mar;
PMID: 40047620
In the field of cell and immunotherapy, chimeric antigen receptor T-cell (CAR-T cell) therapy is the state-of-the-art therapy. It utilizes genetically engineered T cells expressing receptors against specific tumor cell...
2.
Biggi A, Silvestre R, Tirapelle M, Azevedo J, Mogollon Garcia H, Henrique Dos Santos M, et al.
Cytotherapy
. 2024 Jul;
26(11):1320-1330.
PMID: 38970613
Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells has shown promising results in early-phase clinical studies. However, advancing CAR-NK cell therapeutic efficacy is imperative. In this study, we...
3.
Imeri J, Marcoux P, Huyghe M, Desterke C, Fantacini D, Griscelli F, et al.
Front Immunol
. 2024 Jan;
14:1309010.
PMID: 38259442
During the last two decades, the introduction of tyrosine kinase inhibitors (TKIs) to the therapy has changed the natural history of CML but progression into accelerated and blast phase (AP/BP)...
4.
Machado C, da Silva E, Ferreira W, DE Pinho Pessoa F, de Quadros A, Fantacini D, et al.
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067214
Detection of t(9;22), and consequent fusion, is still a marker of worse prognosis for acute lymphoblastic leukemia (ALL), with resistance to tyrosine-kinase inhibitor therapy being a major obstacle in the...
5.
Silvestre R, Eitler J, Azevedo J, Tirapelle M, Fantacini D, de Souza L, et al.
Front Immunol
. 2023 Oct;
14:1226518.
PMID: 37818365
Introduction: Natural killer 92 (NK-92) cells are an attractive therapeutic approach as alternative chimeric antigen receptor (CAR) carriers, different from T cells, once they can be used in the allogeneic...
6.
de Lima S, Fantacini D, Furtado I, Rossetti R, Silveira R, Covas D, et al.
Adv Exp Med Biol
. 2023 Jul;
1429:85-110.
PMID: 37486518
Our current genetic engineering capacity through synthetic biology and genome editing is the foundation of a revolution in biomedical science: the use of genetically programmed cells as therapeutics. The prime...
7.
Artus J, Zenych A, Simanic I, Desterke C, Clay D, Saim S, et al.
Exp Hematol
. 2023 Jun;
124:22-35.e3.
PMID: 37331423
Generating hematopoietic stem cells (HSCs) from pluripotent stem cells (PSCs) has been a long-lasting quest in the field of hematopoiesis. Previous studies suggested that enforced expression of BCR-ABL, the unique...
8.
DE Pinho Pessoa F, Machado C, Barreto I, Sampaio G, DE Sousa Oliveira D, Ribeiro R, et al.
Biomedicines
. 2023 May;
11(4).
PMID: 37189716
Acute myeloid leukemia (AML) is a hematologic malignancy that occurs due to alterations such as genetic mutations, chromosomal translocations, or changes in molecular levels. These alterations can accumulate in stem...
9.
Barbosa H, Piva H, Matsuo F, de Lima S, de Souza L, Osako M, et al.
Int J Biol Macromol
. 2023 May;
242(Pt 1):124647.
PMID: 37146851
Glioblastoma (GBM) is the most common brain cancer characterized by aggressive and infiltrated tumors. For this, hybrid biopolymer-lipid nanoparticles coated with biopolymers such as chitosan and lipidic nanocarriers (LN) loaded...
10.
Manso G, Elias-Oliveira J, Guimaraes J, Pereira I, Rodrigues V, Burger B, et al.
Regen Ther
. 2023 Jan;
22:79-89.
PMID: 36712958
Introduction: Diabetes mellitus (DM) is a chronic disease and a major cause of mortality and morbidity worldwide. The hyperglycemia caused by DM induces micro and macrovascular complications that lead, among...